Moreover, the combination of 25 μM FA and 25 μM Rb1 exhibited a synergistic inhibitory effect, leading to a greater suppression than either agent alone. The FA-Rb1 combination demonstrated significantly enhanced therapeutic efficacy in vivo, exerted improved cardiac function (EF, FS) and myocardial perfusion more effectively than FA alone, and more pronounced reduction in myocardial infarct size, the NR area, and plasma cTnI levels than Rb1 alone. This evidence concerns the gene RB1 and myocardial infarction.